CDKN1B and colorectal carcinoma: Indeed, inhibiting Erk activation through the potent MEK1/2 inhibitor U0126, led to an increased expression of p27Kip1 in all 5 CRC lines with high Erk activity and none of the lines with low Erk activity (Figure 4).